Lord’s Mark secures MHRA registration for its haemodialysis system

Lord’s Mark Industries Limited, through its healthcare and med-tech platform, has secured registration from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its haemodialysis system. The registration covers Renalyx Health Systems Pvt. Ltd. as the manufacturer and includes the system for institutional and home use under GMDN Code 58131. The development could pave the way for the company to enter the UK market and other allied markets, with exports expected to begin in January 20271.Lord’s Mark claims the registration is a first for an Indian company in the AI-powered dialysis segment. It has also linked the development to the India-UK Free Trade Agreement (FTA) 1.What began as a Made-in-India medical technology is now stepping onto the global healthcare stage. Lord’s Mark Industries says it is taking its AI-powered integrated dialysis ecosystem beyond India, with the UK identified as a key market in its international expansion plans1.The development comes as the company builds on the momentum of its Renalyx AI-powered smart haemodialysis technology, which was launched as the technological backbone of an integrated renal-care ecosystem designed to bring together intelligent clinical technology, digital monitoring, operational management and continuity of care.Unlike conventional dialysis models, where the machine operates largely as an individual piece of medical equipment, the Lord’s Mark ecosystem has been conceived as a connected, intelligence-led renal-care platform. At its core is the Renalyx machine, supported by RenalOS, the company’s AI-powered clinical intelligence platform, and an integrated operational model designed to extend care beyond the dialysis session. The ecosystem combines AI clinical intelligence, operational delivery and remote patient monitoring.From machine to intelligence: Reimagining dialysis with AIThe larger vision behind Renalyx is to move dialysis from a machine-centric model towards an intelligence-driven care ecosystem.The technology, the company says, is designed to enable real-time monitoring of treatment parameters, generate predictive alerts and provide data-driven decision support during dialysis sessions.Lord’s Mark says RenalOS is designed to enable AI-led monitoring and support the identification of early warning signals, while connected technology aims to extend monitoring and continuity of care beyond the dialysis centre.. This convergence of AI, connected medical devices, cloud technology and clinical intelligence is at the heart of Lord’s Mark's vision to create a new generation of renal-care infrastructure.And now, that vision is preparing to cross borders.UK: The next frontierWith the MHRA manufacturer and device registration, Lord’s Mark Industries is preparing to explore opportunities to deploy its dialysis technology in the UK, while also evaluating opportunities across UK-allied international markets, subject to applicable regulatory, clinical and market-access requirements. The company’s proposed international business model extends beyond the sale of dialysis machines. Lord’s Mark plans to explore a dual pathway, supplying its Renalyx systems to healthcare providers while also establishing and operating its own dialysis centres. This creates the potential for the company to participate across the renal-care value chain, from medical technology and AI-driven clinical intelligence to infrastructure, centre operations and patient care delivery.India-built. AI-powered. Globally positioned The international push represents another chapter in Lord’s Mark Industries’ broader healthcare strategy: building advanced medical technologies in India that can compete and create impact in global markets.The Renalyx platform has been positioned by the company as an indigenous smart haemodialysis system developed in India, with the broader ecosystem integrating the machine with AI-powered clinical intelligence and managed dialysis operations.Dr. Sachidanand Upadhyay, Managing Director & CEO, Lord’s Mark Industries Limited, said, “This is more than a regulatory milestone for us; it is a moment that validates the larger vision we have been building around Indian medical technology. We started with a simple but powerful belief, that the next generation of healthcare innovation can be built in India and taken to the world. With our AI-powered dialysis ecosystem, we are not merely taking a machine into an international market; we are taking an entirely new approach to how renal care can be connected, intelligent and scalable. The MHRA registration gives us an important platform to explore the UK and UK-allied markets, where we see significant potential for both technology deployment and our own dialysis-centre operations. Our ambition is to make Renalyx a globally recognised Indian healthcare innovation and demonstrate that world-class medical technology can be conceived, engineered and scaled from India.”Building a global renal-care ecosystemLord’s Mark’s international ambition is not limited to exporting equipment. The company is looking to build a scalable renal-care ecosystem that can combine technology deployment with managed healthcare delivery.Through the proposed model, healthcare institutions could potentially access the company’s dialysis technology, while Lord’s Mark can also explore establishing its own centres to deliver technology-enabled dialysis services directly.The company sees this integrated approach as an opportunity to create a more connected ecosystem in which the machine, AI intelligence, clinical workflows, remote monitoring and centre operations work together rather than functioning as isolated components. For India’s med-tech sector, the development also carries a larger significance. As healthcare increasingly adopts AI-enabled technologies, Indian med-tech companies are developing solutions to address domestic healthcare needs while exploring opportunities in international markets2.Lord’s Mark’s UK expansion is, therefore, being positioned as a globalisation journey for an Indian-built healthcare technology platform, taking the company from an indigenous dialysis innovation to an international renal-care business. The MHRA communication confirms that Renalyx Health Systems Pvt. Ltd. is registered as a manufacturer and that its haemodialysis system for institutional/home use is registered1. The MHRA also expressly clarifies that this registration does not itself constitute accreditation, certification or approval by the UK Competent Authority3.For Lord’s Mark Industries, however, the registration marks the beginning of its next ambition: to take an AI-powered Indian dialysis innovation beyond borders and build a global footprint around smarter, connected and scalable renal care.References: Disclaimer: The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.You use AI every day. Now get your AI Quotient. Take the AIQ test.